Search Results - "Ibrahim, M.F.K."

A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer by Clemons, M., Fergusson, D., Simos, D., Mates, M., Robinson, A., Califaretti, N., Zibdawi, L., Bahl, M., Raphael, J., Ibrahim, M.F.K., Fernandes, R., Pitre, L., Aseyev, O., Stober, C., Vandermeer, L., Saunders, D., Hutton, B., Mallick, R., Pond, G.R., Awan, A., Hilton, J.

“…The optimal duration of filgrastim as primary febrile neutropenia (FN) prophylaxis in early breast cancer patients is unknown, with 5, 7 or 10 days being…”
Get full text

Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis by Ibrahim, M.F.K., Mazzarello, S., Shorr, R., Vandermeer, L., Jacobs, C., Hilton, J., Hutton, B., Clemons, M.

“…De-escalation of bone-targeted agents, such as bisphosphonates and denosumab, from 4- to 12-weekly dosing is an increasingly used strategy in patients with…”
Get full text

Optimal sequence of adjuvant endocrine and radiation therapy in early-stage breast cancer – A systematic review by McGee, S.F., Mazzarello, S., Caudrelier, J.M., Lima, M.A.G., Hutton, B., Sienkiewicz, M., Stober, C., Fernandes, R., Ibrahim, M.F.K., Vandermeer, L., Hilton, J., Shorr, R., Fergusson, D., Clemons, M.

“…•Clinical equipoise exists around the optimal timing of starting endocrine therapy in patients receiving post-operative radiation therapy.•Theoretical concerns…”
Get full text

Biomarkers for afatinib and dasatinib treatment in triple negative breast cancer by Canonici, A., Ibrahim, M.F.K., Fanning, K., Cremona, M., Morgan, C., Hennessy, B., Solca, F., Crown, J., O'Donovan, N.

Get full text